EpiDestiny
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | DNMT1 (DNA methyltransferase 1)Small molecule | Sickle Cell Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
June 2026PresentationDecitabine/Tetrahydrouridine (NDec)ASCENT1 Phase 2 (NCT05405114) results at EHA 2026: hemoglobin up 0.97 g/dL with the twice-weekly-cycle regimen
Financial reports
No financial reports recorded.